Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Community-Acquired Pneumonia Treatment Guidelines

Introduction to Treatment

  • The American Thoracic Society recommends combination therapy with a beta-lactam antibiotic plus a macrolide for community-acquired pneumonia, with treatment duration of 5-7 days for non-severe cases and 10-14 days for severe cases 1, 2, 3

Treatment Based on Severity and Setting

  • For non-severe community-acquired pneumonia, the Infectious Diseases Society of America recommends amoxicillin monotherapy as the preferred agent for patients who can be managed in the community 4
  • For penicillin-allergic patients, a macrolide is recommended as an alternative 4
  • Treatment duration should be 7 days for uncomplicated community-managed pneumonia 2, 4
  • Oral therapy is appropriate from the beginning for ambulatory patients 3, 5
  • For severe community-acquired pneumonia, immediate parenteral antibiotic administration is required 2, 3
  • An intravenous combination of a broad-spectrum β-lactamase stable antibiotic together with a macrolide is preferred 2, 3, 6

Special Considerations

  • Patients should be switched from intravenous to oral therapy when they are hemodynamically stable and improving clinically 1
  • Minimum treatment duration should be 5 days 1, 4
  • Patient should be afebrile for 48-72 hours before discontinuation 1, 4

Monitoring Response to Treatment

  • Monitor response using simple clinical criteria, including body temperature 2, respiratory parameters 4, and hemodynamic parameters 3, 5
  • C-reactive protein should be measured on days one and three/four, especially in patients with unfavorable clinical parameters 3, 5

Prevention Strategies

  • Influenza vaccination is recommended for elderly patients and those at "high risk" of mortality from influenza or complicating pneumonia 2, 6, 4
  • Pneumococcal vaccination is recommended for all those aged 2 years or older in whom pneumococcal infection is likely to be more common or serious 2, 6, 4